-$0.32 EPS Expected for Dicerna Pharmaceuticals Inc (DRNA) This Quarter

Wall Street analysts forecast that Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) will report earnings per share of ($0.32) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Dicerna Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.12) and the lowest estimate coming in at ($0.58). Dicerna Pharmaceuticals reported earnings per share of ($0.28) in the same quarter last year, which would suggest a negative year-over-year growth rate of 14.3%. The business is scheduled to report its next earnings report on Wednesday, August 14th.

Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.16). The company had revenue of $3.11 million during the quarter, compared to analyst estimates of $10.59 million. Dicerna Pharmaceuticals had a negative return on equity of 52.17% and a negative net margin of 1,284.93%.



A number of brokerages recently weighed in on DRNA. Citigroup reaffirmed a “buy” rating and issued a $30.00 target price on shares of Dicerna Pharmaceuticals in a research note on Friday. SunTrust Banks reduced their target price on shares of Dicerna Pharmaceuticals to $20.00 and set a “buy” rating for the company in a research note on Thursday, May 16th. Zacks Investment Research lowered shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 15th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of Dicerna Pharmaceuticals in a research note on Friday, May 3rd. Finally, ValuEngine lowered shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, April 26th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. Dicerna Pharmaceuticals has an average rating of “Buy” and an average price target of $21.38.

NASDAQ DRNA traded up $0.66 on Friday, reaching $12.49. The company had a trading volume of 649,960 shares, compared to its average volume of 494,323. The firm has a market cap of $853.37 million, a PE ratio of -10.41 and a beta of 2.30. The company has a current ratio of 5.00, a quick ratio of 5.00 and a debt-to-equity ratio of 0.01. Dicerna Pharmaceuticals has a 1-year low of $9.31 and a 1-year high of $17.98.

In other news, insider James B. Weissman sold 15,000 shares of the stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $15.00, for a total transaction of $225,000.00. Following the completion of the transaction, the insider now directly owns 39,480 shares in the company, valued at approximately $592,200. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 19.85% of the company’s stock.

Several institutional investors have recently bought and sold shares of DRNA. Bank of New York Mellon Corp raised its holdings in shares of Dicerna Pharmaceuticals by 15.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 185,441 shares of the biopharmaceutical company’s stock valued at $2,830,000 after purchasing an additional 24,543 shares during the period. MetLife Investment Advisors LLC raised its holdings in shares of Dicerna Pharmaceuticals by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 33,686 shares of the biopharmaceutical company’s stock valued at $514,000 after purchasing an additional 11,975 shares during the period. Teachers Advisors LLC raised its holdings in shares of Dicerna Pharmaceuticals by 8.8% in the 3rd quarter. Teachers Advisors LLC now owns 92,479 shares of the biopharmaceutical company’s stock valued at $1,411,000 after purchasing an additional 7,475 shares during the period. Vanguard Group Inc. raised its holdings in shares of Dicerna Pharmaceuticals by 40.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,983,272 shares of the biopharmaceutical company’s stock valued at $30,265,000 after purchasing an additional 573,197 shares during the period. Finally, Federated Investors Inc. PA raised its holdings in shares of Dicerna Pharmaceuticals by 61,484.1% in the 3rd quarter. Federated Investors Inc. PA now owns 252,495 shares of the biopharmaceutical company’s stock valued at $3,853,000 after purchasing an additional 252,085 shares during the period. Institutional investors own 89.65% of the company’s stock.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Further Reading: What are retained earnings?

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.